Cognition Therapeutics Inc financial data

Symbol
CGTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2403 Sidney Street, Suite 261, Pittsburgh, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Former names
COGNITION THERAPUTICS INC (to 12/28/2010)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 365 % -29.5%
Debt-to-equity 39.8 % +35.8%
Return On Equity -118 % -94.7%
Return On Assets -84.5 % -80.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.1M shares +32.4%
Common Stock, Shares, Outstanding 40.1M shares +32.4%
Entity Public Float 43.1M USD +12.8%
Common Stock, Value, Issued 40K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 40.1M shares +35.3%
Weighted Average Number of Shares Outstanding, Diluted 40.1M shares +35.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 45.4M USD +58.5%
General and Administrative Expense 13.3M USD -5.43%
Operating Income (Loss) -58.7M USD -37.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.73M USD +19.6%
Income Tax Expense (Benefit) -125K USD
Net Income (Loss) Attributable to Parent -31.1M USD -36.9%
Earnings Per Share, Basic -0.94 USD/shares -9.3%
Earnings Per Share, Diluted -0.94 USD/shares -9.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.5M USD -23.3%
Assets, Current 33.6M USD -19.3%
Property, Plant and Equipment, Net 234K USD -5.65%
Operating Lease, Right-of-Use Asset 585K USD -20.5%
Assets 34.4M USD -21.8%
Accounts Payable, Current 3.03M USD -25.3%
Employee-related Liabilities, Current 1.09M USD +30.2%
Accrued Liabilities, Current 6.06M USD +151%
Liabilities, Current 10.9M USD +38%
Deferred Income Tax Liabilities, Net 147K USD -17.4%
Operating Lease, Liability, Noncurrent 440K USD -27.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 11.4M USD +18.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -195K USD +2.01%
Retained Earnings (Accumulated Deficit) -157M USD -24.6%
Stockholders' Equity Attributable to Parent 23M USD -33.1%
Liabilities and Equity 34.4M USD -21.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.24M USD -168%
Net Cash Provided by (Used in) Financing Activities 12M USD
Net Cash Provided by (Used in) Investing Activities -41K USD +69.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 40.1M shares +32.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.75M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.5M USD -23.3%
Deferred Tax Assets, Valuation Allowance 22.2M USD +35.1%
Deferred Tax Assets, Gross 22.4M USD +34.6%
Operating Lease, Liability 624K USD -19.4%
Payments to Acquire Property, Plant, and Equipment 41K USD -69.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.9M USD -36.1%
Lessee, Operating Lease, Liability, to be Paid 718K USD -22%
Property, Plant and Equipment, Gross 1.33M USD +12.4%
Operating Lease, Liability, Current 184K USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD -28.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 226K USD +2.26%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 94K USD -35.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 91K USD -40.9%
Deferred Tax Assets, Operating Loss Carryforwards 6.85M USD -16.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 92K USD +5.75%
Operating Lease, Payments 56K USD +12%
Additional Paid in Capital 180M USD +12.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 27K USD +28.6%
Deferred Tax Assets, Net of Valuation Allowance 147K USD -17.4%
Share-based Payment Arrangement, Expense 1.15M USD +11.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%